Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pediatr Infect Dis J ; 43(8): 715-719, 2024 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-38567978

RESUMEN

BACKGROUND: We aimed to investigate the clinical features, antimicrobial susceptibility and pvl gene expression in Staphylococcus aureus causing acute hematogenous bone and joint infections (BJIs) in children in Vietnam. METHODS: In this prospective study, the demographics, microbiology and clinical outcomes of pediatric patients with acute hematogenous BJIs were collected from September 2022 to September 2023. Antimicrobial susceptibility profiles were determined using VITEK2 Compact system. The pvl gene encoding the Panton-Valentine leukocidin (PVL) toxin was detected by using polymerase chain reaction. Mann-Whitney, χ 2 and Fisher test were used for statistical analysis. RESULTS: In total, 78 patients (46 boys) with S. aureus acute hematogenous BJIs were recruited at the National Children's Hospital, Hanoi, Vietnam. Of all S. aureus isolates, 84.6% were methicillin-resistant S. aureus . All S. aureus isolates were susceptible to vancomycin, ciprofloxacin and levofloxacin; 97% of methicillin-resistant S. aureus isolates was resistant to clindamycin (minimum inhibitory concentration ≥8 µg/mL). The pvl gene was detected in 83.3% of isolates, including 57 methicillin-resistant S. aureus isolates. Patients in the pvl -positive group had significantly higher C-reactive protein levels than those in the pvl -negative group ( P = 0.04). In addition, all 8 children with septic shock were infected with pvl -positive S. aureus . CONCLUSIONS: PVL is a prevalent virulence factor of S. aureus in Vietnam. Furthermore, high inflammatory parameters (C-reactive protein) may be present at the time of diagnosis in PVL positivity-related acute hematogenous BJIs. Further research is necessary to enhance our understanding of the varying correlations between virulence factors and outcomes of S. aureus BJIs.


Asunto(s)
Antibacterianos , Toxinas Bacterianas , Exotoxinas , Hospitales Pediátricos , Leucocidinas , Pruebas de Sensibilidad Microbiana , Infecciones Estafilocócicas , Staphylococcus aureus , Centros de Atención Terciaria , Humanos , Leucocidinas/genética , Exotoxinas/genética , Vietnam/epidemiología , Masculino , Femenino , Toxinas Bacterianas/genética , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/epidemiología , Preescolar , Staphylococcus aureus/genética , Staphylococcus aureus/efectos de los fármacos , Estudios Prospectivos , Niño , Centros de Atención Terciaria/estadística & datos numéricos , Prevalencia , Lactante , Antibacterianos/farmacología , Artritis Infecciosa/microbiología , Artritis Infecciosa/epidemiología , Adolescente , Osteomielitis/microbiología , Osteomielitis/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA